

Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Growth 2023-2029

<https://marketpublishers.com/r/GEF641803A5EEN.html>

Date: February 2023

Pages: 90

Price: US\$ 3,660.00 (Single User License)

ID: GEF641803A5EEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Non-alcoholic steatohepatitis is an advanced stage of non-alcoholic fatty liver disease (NAFLD), which arises when the excess fat accumulation causes inflammation and damage leading to liver scarring. A biomarker is the most effective diagnosis tool for measuring the biological state and is termed as an indicator for measuring normal biological processes and pathogenic process in the body.

LPI (LP Information)' newest research report, the "NASH (Non-alcoholic Steatohepatitis) Biomarkers Industry Forecast" looks at past sales and reviews total world NASH (Non-alcoholic Steatohepatitis) Biomarkers sales in 2022, providing a comprehensive analysis by region and market sector of projected NASH (Non-alcoholic Steatohepatitis) Biomarkers sales for 2023 through 2029. With NASH (Non-alcoholic Steatohepatitis) Biomarkers sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world NASH (Non-alcoholic Steatohepatitis) Biomarkers industry.

This Insight Report provides a comprehensive analysis of the global NASH (Non-alcoholic Steatohepatitis) Biomarkers landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on NASH (Non-alcoholic Steatohepatitis) Biomarkers portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global NASH (Non-alcoholic Steatohepatitis) Biomarkers market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for NASH (Non-alcoholic Steatohepatitis) Biomarkers and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global NASH (Non-alcoholic Steatohepatitis) Biomarkers.

The global NASH (Non-alcoholic Steatohepatitis) Biomarkers market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for NASH (Non-alcoholic Steatohepatitis) Biomarkers is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for NASH (Non-alcoholic Steatohepatitis) Biomarkers is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for NASH (Non-alcoholic Steatohepatitis) Biomarkers is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key NASH (Non-alcoholic Steatohepatitis) Biomarkers players cover GENFIT SA, Gilead Sciences, Inc. (GILD), AstraZeneca, Novartis AG, Bristol-Myers Squibb Company, Allergan Plc, Novo Nordisk A/S, Boehringer Ingelheim and Pfizer Inc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of NASH (Non-alcoholic Steatohepatitis) Biomarkers market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Serum Biomarkers

Hepatic Fibrosis Biomarkers

Apoptosis Biomarkers

Oxidative Stress Biomarkers

Others

Segmentation by application

Pharma & CRO Industry

Hospitals

Diagnostic Labs

Academic Research Institutes

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

GENFIT SA

Gilead Sciences, Inc. (GILD)

AstraZeneca

Novartis AG

Bristol-Myers Squibb Company

Allergan Plc

Novo Nordisk A/S

Boehringer Ingelheim

Pfizer Inc

Key Questions Addressed in this Report

What is the 10-year outlook for the global NASH (Non-alcoholic Steatohepatitis) Biomarkers market?

What factors are driving NASH (Non-alcoholic Steatohepatitis) Biomarkers market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do NASH (Non-alcoholic Steatohepatitis) Biomarkers market opportunities vary by end market size?

How does NASH (Non-alcoholic Steatohepatitis) Biomarkers break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

2.1.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Sales 2018-2029

2.1.2 World Current & Future Analysis for NASH (Non-alcoholic Steatohepatitis) Biomarkers by Geographic Region, 2018, 2022 & 2029

2.1.3 World Current & Future Analysis for NASH (Non-alcoholic Steatohepatitis) Biomarkers by Country/Region, 2018, 2022 & 2029

2.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Segment by Type

2.2.1 Serum Biomarkers

2.2.2 Hepatic Fibrosis Biomarkers

2.2.3 Apoptosis Biomarkers

2.2.4 Oxidative Stress Biomarkers

2.2.5 Others

2.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type

2.3.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2018-2023)

2.3.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Market Share by Type (2018-2023)

2.3.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sale Price by Type (2018-2023)

2.4 NASH (Non-alcoholic Steatohepatitis) Biomarkers Segment by Application

2.4.1 Pharma & CRO Industry

2.4.2 Hospitals

2.4.3 Diagnostic Labs

2.4.4 Academic Research Institutes

2.5 NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application

2.5.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sale Market Share by Application (2018-2023)

2.5.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue and Market Share by Application (2018-2023)

2.5.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sale Price by Application (2018-2023)

3 GLOBAL NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS BY COMPANY

3.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Breakdown Data by Company

3.1.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Sales by Company (2018-2023)

3.1.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Company (2018-2023)

3.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Revenue by Company (2018-2023)

3.2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Company (2018-2023)

3.2.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Company (2018-2023)

3.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sale Price by Company

3.4 Key Manufacturers NASH (Non-alcoholic Steatohepatitis) Biomarkers Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Location Distribution

3.4.2 Players NASH (Non-alcoholic Steatohepatitis) Biomarkers Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS BY GEOGRAPHIC REGION

4.1 World Historic NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Geographic Region (2018-2023)

4.1.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Sales by Geographic Region (2018-2023)

4.1.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Revenue by Geographic Region (2018-2023)

4.2 World Historic NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Country/Region (2018-2023)

4.2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Sales by Country/Region (2018-2023)

4.2.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Revenue by Country/Region (2018-2023)

4.3 Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Growth

4.4 APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Growth

4.5 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Growth

4.6 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Growth

5 AMERICAS

5.1 Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country

5.1.1 Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2018-2023)

5.1.2 Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2018-2023)

5.2 Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type

5.3 Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region

6.1.1 APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2018-2023)

6.1.2 APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2018-2023)

- 6.2 APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type
- 6.3 APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers by Country
 - 7.1.1 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2018-2023)
 - 7.1.2 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2018-2023)
- 7.2 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type
- 7.3 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers by Country
 - 8.1.1 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2018-2023)
 - 8.1.2 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2018-2023)
- 8.2 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type
- 8.3 Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of NASH (Non-alcoholic Steatohepatitis) Biomarkers

10.3 Manufacturing Process Analysis of NASH (Non-alcoholic Steatohepatitis) Biomarkers

10.4 Industry Chain Structure of NASH (Non-alcoholic Steatohepatitis) Biomarkers

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Distributors

11.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Customer

12 WORLD FORECAST REVIEW FOR NASH (NON-ALCOHOLIC STEATOHEPATITIS) BIOMARKERS BY GEOGRAPHIC REGION

12.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size Forecast by Region

12.1.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Forecast by Region (2024-2029)

12.1.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Revenue Forecast by Region (2024-2029)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Forecast by Type

12.7 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 GENFIT SA

13.1.1 GENFIT SA Company Information

13.1.2 GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications

13.1.3 GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2018-2023)

13.1.4 GENFIT SA Main Business Overview

13.1.5 GENFIT SA Latest Developments

13.2 Gilead Sciences, Inc. (GILD)

13.2.1 Gilead Sciences, Inc. (GILD) Company Information

13.2.2 Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications

13.2.3 Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2018-2023)

13.2.4 Gilead Sciences, Inc. (GILD) Main Business Overview

13.2.5 Gilead Sciences, Inc. (GILD) Latest Developments

13.3 AstraZeneca

13.3.1 AstraZeneca Company Information

13.3.2 AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications

13.3.3 AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2018-2023)

13.3.4 AstraZeneca Main Business Overview

13.3.5 AstraZeneca Latest Developments

13.4 Novartis AG

13.4.1 Novartis AG Company Information

13.4.2 Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications

13.4.3 Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2018-2023)

13.4.4 Novartis AG Main Business Overview

13.4.5 Novartis AG Latest Developments

13.5 Bristol-Myers Squibb Company

13.5.1 Bristol-Myers Squibb Company Company Information

- 13.5.2 Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
- 13.5.3 Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.5.4 Bristol-Myers Squibb Company Main Business Overview
- 13.5.5 Bristol-Myers Squibb Company Latest Developments
- 13.6 Allergan Plc
 - 13.6.1 Allergan Plc Company Information
 - 13.6.2 Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
 - 13.6.3 Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.6.4 Allergan Plc Main Business Overview
 - 13.6.5 Allergan Plc Latest Developments
- 13.7 Novo Nordisk A/S
 - 13.7.1 Novo Nordisk A/S Company Information
 - 13.7.2 Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
 - 13.7.3 Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.7.4 Novo Nordisk A/S Main Business Overview
 - 13.7.5 Novo Nordisk A/S Latest Developments
- 13.8 Boehringer Ingelheim
 - 13.8.1 Boehringer Ingelheim Company Information
 - 13.8.2 Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
 - 13.8.3 Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.8.4 Boehringer Ingelheim Main Business Overview
 - 13.8.5 Boehringer Ingelheim Latest Developments
- 13.9 Pfizer Inc
 - 13.9.1 Pfizer Inc Company Information
 - 13.9.2 Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications
 - 13.9.3 Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.9.4 Pfizer Inc Main Business Overview
 - 13.9.5 Pfizer Inc Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)
- Table 2. NASH (Non-alcoholic Steatohepatitis) Biomarkers Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)
- Table 3. Major Players of Serum Biomarkers
- Table 4. Major Players of Hepatic Fibrosis Biomarkers
- Table 5. Major Players of Apoptosis Biomarkers
- Table 6. Major Players of Oxidative Stress Biomarkers
- Table 7. Major Players of Others
- Table 8. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2018-2023) & (K Units)
- Table 9. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2018-2023)
- Table 10. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Type (2018-2023) & (\$ million)
- Table 11. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Type (2018-2023)
- Table 12. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sale Price by Type (2018-2023) & (USD/Unit)
- Table 13. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2018-2023) & (K Units)
- Table 14. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2018-2023)
- Table 15. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Application (2018-2023)
- Table 16. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Application (2018-2023)
- Table 17. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sale Price by Application (2018-2023) & (USD/Unit)
- Table 18. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Company (2018-2023) & (K Units)
- Table 19. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Company (2018-2023)
- Table 20. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Company (2018-2023) (\$ Millions)

Table 21. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Company (2018-2023)

Table 22. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sale Price by Company (2018-2023) & (USD/Unit)

Table 23. Key Manufacturers NASH (Non-alcoholic Steatohepatitis) Biomarkers Producing Area Distribution and Sales Area

Table 24. Players NASH (Non-alcoholic Steatohepatitis) Biomarkers Products Offered

Table 25. NASH (Non-alcoholic Steatohepatitis) Biomarkers Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

Table 26. New Products and Potential Entrants

Table 27. Mergers & Acquisitions, Expansion

Table 28. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Geographic Region (2018-2023) & (K Units)

Table 29. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share Geographic Region (2018-2023)

Table 30. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Geographic Region (2018-2023) & (\$ millions)

Table 31. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Geographic Region (2018-2023)

Table 32. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country/Region (2018-2023) & (K Units)

Table 33. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country/Region (2018-2023)

Table 34. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country/Region (2018-2023) & (\$ millions)

Table 35. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country/Region (2018-2023)

Table 36. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2018-2023) & (K Units)

Table 37. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country (2018-2023)

Table 38. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2018-2023) & (\$ Millions)

Table 39. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country (2018-2023)

Table 40. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2018-2023) & (K Units)

Table 41. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2018-2023) & (K Units)

Table 42. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2018-2023) & (K Units)

Table 43. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Region (2018-2023)

Table 44. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Region (2018-2023) & (\$ Millions)

Table 45. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Region (2018-2023)

Table 46. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2018-2023) & (K Units)

Table 47. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2018-2023) & (K Units)

Table 48. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2018-2023) & (K Units)

Table 49. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country (2018-2023)

Table 50. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2018-2023) & (\$ Millions)

Table 51. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country (2018-2023)

Table 52. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2018-2023) & (K Units)

Table 53. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2018-2023) & (K Units)

Table 54. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Country (2018-2023) & (K Units)

Table 55. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country (2018-2023)

Table 56. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue by Country (2018-2023) & (\$ Millions)

Table 57. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country (2018-2023)

Table 58. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Type (2018-2023) & (K Units)

Table 59. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Application (2018-2023) & (K Units)

Table 60. Key Market Drivers & Growth Opportunities of NASH (Non-alcoholic Steatohepatitis) Biomarkers

Table 61. Key Market Challenges & Risks of NASH (Non-alcoholic Steatohepatitis)

Biomarkers

Table 62. Key Industry Trends of NASH (Non-alcoholic Steatohepatitis) Biomarkers

Table 63. NASH (Non-alcoholic Steatohepatitis) Biomarkers Raw Material

Table 64. Key Suppliers of Raw Materials

Table 65. NASH (Non-alcoholic Steatohepatitis) Biomarkers Distributors List

Table 66. NASH (Non-alcoholic Steatohepatitis) Biomarkers Customer List

Table 67. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Forecast by Region (2024-2029) & (K Units)

Table 68. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 69. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Forecast by Country (2024-2029) & (K Units)

Table 70. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 71. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Forecast by Region (2024-2029) & (K Units)

Table 72. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 73. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Forecast by Country (2024-2029) & (K Units)

Table 74. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 75. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Forecast by Country (2024-2029) & (K Units)

Table 76. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 77. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Forecast by Type (2024-2029) & (K Units)

Table 78. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Forecast by Type (2024-2029) & (\$ Millions)

Table 79. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Forecast by Application (2024-2029) & (K Units)

Table 80. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Forecast by Application (2024-2029) & (\$ Millions)

Table 81. GENFIT SA Basic Information, NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base, Sales Area and Its Competitors

Table 82. GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications

Table 83. GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K

Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 84. GENFIT SA Main Business

Table 85. GENFIT SA Latest Developments

Table 86. Gilead Sciences, Inc. (GILD) Basic Information, NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base, Sales Area and Its Competitors

Table 87. Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications

Table 88. Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 89. Gilead Sciences, Inc. (GILD) Main Business

Table 90. Gilead Sciences, Inc. (GILD) Latest Developments

Table 91. AstraZeneca Basic Information, NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base, Sales Area and Its Competitors

Table 92. AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications

Table 93. AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 94. AstraZeneca Main Business

Table 95. AstraZeneca Latest Developments

Table 96. Novartis AG Basic Information, NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base, Sales Area and Its Competitors

Table 97. Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications

Table 98. Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 99. Novartis AG Main Business

Table 100. Novartis AG Latest Developments

Table 101. Bristol-Myers Squibb Company Basic Information, NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base, Sales Area and Its Competitors

Table 102. Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications

Table 103. Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 104. Bristol-Myers Squibb Company Main Business

Table 105. Bristol-Myers Squibb Company Latest Developments

Table 106. Allergan Plc Basic Information, NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base, Sales Area and Its Competitors

Table 107. Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications

Table 108. Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 109. Allergan Plc Main Business

Table 110. Allergan Plc Latest Developments

Table 111. Novo Nordisk A/S Basic Information, NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base, Sales Area and Its Competitors

Table 112. Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications

Table 113. Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 114. Novo Nordisk A/S Main Business

Table 115. Novo Nordisk A/S Latest Developments

Table 116. Boehringer Ingelheim Basic Information, NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base, Sales Area and Its Competitors

Table 117. Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications

Table 118. Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 119. Boehringer Ingelheim Main Business

Table 120. Boehringer Ingelheim Latest Developments

Table 121. Pfizer Inc Basic Information, NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base, Sales Area and Its Competitors

Table 122. Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Portfolios and Specifications

Table 123. Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 124. Pfizer Inc Main Business

Table 125. Pfizer Inc Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of NASH (Non-alcoholic Steatohepatitis) Biomarkers

Figure 2. NASH (Non-alcoholic Steatohepatitis) Biomarkers Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Growth Rate 2018-2029 (K Units)

Figure 7. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth Rate 2018-2029 (\$ Millions)

Figure 8. NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales by Region (2018, 2022 & 2029) & (\$ Millions)

Figure 9. Product Picture of Serum Biomarkers

Figure 10. Product Picture of Hepatic Fibrosis Biomarkers

Figure 11. Product Picture of Apoptosis Biomarkers

Figure 12. Product Picture of Oxidative Stress Biomarkers

Figure 13. Product Picture of Others

Figure 14. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type in 2022

Figure 15. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Type (2018-2023)

Figure 16. NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumed in Pharma & CRO Industry

Figure 17. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market: Pharma & CRO Industry (2018-2023) & (K Units)

Figure 18. NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumed in Hospitals

Figure 19. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market: Hospitals (2018-2023) & (K Units)

Figure 20. NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumed in Diagnostic Labs

Figure 21. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market: Diagnostic Labs (2018-2023) & (K Units)

Figure 22. NASH (Non-alcoholic Steatohepatitis) Biomarkers Consumed in Academic Research Institutes

Figure 23. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market: Academic Research Institutes (2018-2023) & (K Units)

Figure 24. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2022)

Figure 25. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Application in 2022

Figure 26. NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market by Company in 2022 (K Units)

Figure 27. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Company in 2022

Figure 28. NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market by Company in 2022 (\$ Million)

Figure 29. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Company in 2022

Figure 30. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Geographic Region (2018-2023)

Figure 31. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Geographic Region in 2022

Figure 32. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales 2018-2023 (K Units)

Figure 33. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue 2018-2023 (\$ Millions)

Figure 34. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales 2018-2023 (K Units)

Figure 35. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue 2018-2023 (\$ Millions)

Figure 36. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales 2018-2023 (K Units)

Figure 37. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue 2018-2023 (\$ Millions)

Figure 38. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales 2018-2023 (K Units)

Figure 39. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue 2018-2023 (\$ Millions)

Figure 40. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country in 2022

Figure 41. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country in 2022

Figure 42. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2018-2023)

Figure 43. Americas NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market

Share by Application (2018-2023)

Figure 44. United States NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 (\$ Millions)

Figure 45. Canada NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 (\$ Millions)

Figure 46. Mexico NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 (\$ Millions)

Figure 47. Brazil NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 (\$ Millions)

Figure 48. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Region in 2022

Figure 49. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Regions in 2022

Figure 50. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2018-2023)

Figure 51. APAC NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2018-2023)

Figure 52. China NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 (\$ Millions)

Figure 53. Japan NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 (\$ Millions)

Figure 54. South Korea NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 (\$ Millions)

Figure 55. Southeast Asia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 (\$ Millions)

Figure 56. India NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 (\$ Millions)

Figure 57. Australia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 (\$ Millions)

Figure 58. China Taiwan NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 (\$ Millions)

Figure 59. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country in 2022

Figure 60. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country in 2022

Figure 61. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2018-2023)

Figure 62. Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2018-2023)

Figure 63. Germany NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 (\$ Millions)

Figure 64. France NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 (\$ Millions)

Figure 65. UK NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 (\$ Millions)

Figure 66. Italy NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 (\$ Millions)

Figure 67. Russia NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 (\$ Millions)

Figure 68. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Country in 2022

Figure 69. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share by Country in 2022

Figure 70. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Type (2018-2023)

Figure 71. Middle East & Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Share by Application (2018-2023)

Figure 72. Egypt NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 (\$ Millions)

Figure 73. South Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 (\$ Millions)

Figure 74. Israel NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 (\$ Millions)

Figure 75. Turkey NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 (\$ Millions)

Figure 76. GCC Country NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Growth 2018-2023 (\$ Millions)

Figure 77. Manufacturing Cost Structure Analysis of NASH (Non-alcoholic Steatohepatitis) Biomarkers in 2022

Figure 78. Manufacturing Process Analysis of NASH (Non-alcoholic Steatohepatitis) Biomarkers

Figure 79. Industry Chain Structure of NASH (Non-alcoholic Steatohepatitis) Biomarkers

Figure 80. Channels of Distribution

Figure 81. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market Forecast by Region (2024-2029)

Figure 82. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market Share Forecast by Region (2024-2029)

Figure 83. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market

Share Forecast by Type (2024-2029)

Figure 84. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market

Share Forecast by Type (2024-2029)

Figure 85. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Market

Share Forecast by Application (2024-2029)

Figure 86. Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue Market

Share Forecast by Application (2024-2029)

I would like to order

Product name: Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/GEF641803A5EEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GEF641803A5EEN.html>